PFE buyout of MNKD makes way more sense that the bid they made for AstraZ
Pfizer is the leading pain management seller, and big stakes in the vaccine markets, and can get back in an improved and popular inhaled insulin approval by FDA. Pfizer's approved drugs delivered through Technosphere inhaled platform would make them very very wealthy! Let's see if PFE is smart enough to go after MNKD before they miss out. MNKD inhalable technology is a real threat to PFE sales, but they could be a big positive for their sales with a partner or buyout with MNKD.
LONDON, Aug 2 (APM) - Novo Nordisk said on Wednesday it was suing Pfizer in a bid to
stop the U.S. group marketing its inhaled insulin, Exubera.
In a statement, the Danish group said: "On 1 August Novo Nordisk filed a lawsuit against
Pfizer claiming that Pfizer's product Exubera infringes Novo Nordisk's patents covering
inhaled insulin treatment for diabetes.
"The lawsuit, filed in United States Federal Court in the Southern District of New York,
alleges that Pfizer wilfully and deliberately infringed the patents."
POSSIBLE INJUNCTION ON EXUBERA SALES IN TWO WEEKS
General Council for Novo, Ole Ramsby, told APM the lawsuit included a motion for a
preliminary injunction to stop Pfizer marketing Exubera in the U.S.
"We expect a decision (from the court) in a couple of weeks. We do expect to win the
injunction. We think we can demonstrate a clear infringement by Pfizer," the lawyer said.
Ramsby said Novo holds five patents related to inhaled insulin which give intellectual
protection to 2013. The patents come from Novo's long-term partnership with California
biotech, Aradigm, and Pfizer has broken all five, he added.
The Danish company's rival inhaled insulin is still in Phase III trials and Ramsby could not
say when it will be launched. However, he said the result of being second to market in the
U.S. after Pfizer were grave.
"Every customer on Exubera is a customer lost to us ... we will suffer irreparable harm if the
injunction is not granted."
Asked why Novo had taken so long to take legal action, Ramsby said that for legal reasons
the company had to wait until Pfizer began telling physicians about its new product.
Nobody from Pfizer was immediately available to comment.
Exubera, which Pfizer acquired from Sanofi-Aventis, was recently launched in Germany, its
first major EU market, and is set to be rolled out in the United States in September.
The world's first inhaled insulin is one of the key products that Pfizer is relying on for
continued growth followin